{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:57:33Z","timestamp":1778155053857,"version":"3.51.4"},"reference-count":115,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,6,15]],"date-time":"2007-06-15T00:00:00Z","timestamp":1181865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemodialysis International"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) infection is a global health problem, common worldwide, leading to acute and chronic hepatitis and its consequences of hepatocirrhosis and hepatocellular carcinoma. Patients on hemodialysis belong to the high\u2010risk group of HCV infection. The prevalence of HCV infection in dialysis patients ranges from 4% to more than 70% in some countries. The main reasons for such a high incidence of infections are a high prevalence of HCV infection in the general population, lack of standard infection precautions and effective vaccination, inadequate disinfection procedures of dialysis machines and other medical equipment, as well as spread of infection from patient to patient, especially in dialytic centers with a high percentage of infected patients. The diagnostic procedures useful in the evaluation of HCV infection are detection of anti\u2010HCV antibodies, identification of HCV RNA, counts of virus copies, and identification of its genome. From the 6 major genotypes and multiple subtypes of the HCV, genotypes 1a and 1b are the most common in Europe and Japan, and 1b is responsible for more severe liver disease and aggressive course leading to liver fibrosis. Antiviral therapy of HCV+ dialysis patients with interferon\u2010\u03b1 (INF\u2010\u03b1) gives slightly better results than in the general population, but is poorly tolerated and associated with side effects. Although ribavirin in not recommended for dialysis patients, the addition of small doses of this compound to pegylated INF is discussed, especially for patients in whom previous infection treatment failed.<\/jats:p>","DOI":"10.1111\/j.1542-4758.2007.00181.x","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T13:50:43Z","timestamp":1182001843000},"page":"286-295","source":"Crossref","is-referenced-by-count":17,"title":["Hepatitis C virus infection in dialysis patients"],"prefix":"10.1111","volume":"11","author":[{"given":"W\u0142adys\u0142aw","family":"SU\u0141OWICZ","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"RADZISZEWSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"CHOWANIEC","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp4.19"},{"key":"e_1_2_7_3_2","first-page":"65","volume":"72","author":"World Health Organization.","year":"1997","journal-title":"Hepatitis C global prevalence. Wkly Epidemiol Rep"},{"key":"e_1_2_7_4_2","first-page":"106","article-title":"Hepatitis C virus","volume":"218","author":"Cooreman MP","year":"1996","journal-title":"Biological and clinical consequences of genetic heterogeneity"},{"issue":"1","key":"e_1_2_7_5_2","first-page":"25","article-title":"National Institutes of Health Consensus Development Conference Panel statement","volume":"26","author":"National Institutes of Health Consensus Development Conference Panel.","year":"1997","journal-title":"Management of hepatitis C"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_7_7_2","first-page":"244","article-title":"HCV infection","volume":"81","author":"Brugnano R","year":"1999","journal-title":"\u2018Six years after\u2019 in a dialysis unit"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.12"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0188-4409(00)00100-4"},{"key":"e_1_2_7_10_2","first-page":"373","article-title":"Fifteen years of investigations on hepatitis C virus in Poland","volume":"59","author":"Juszczyk J.","year":"2005","journal-title":"Przegl Epidemiol"},{"key":"e_1_2_7_11_2","first-page":"458","article-title":"Hepatitis C genotypes","volume":"71","author":"Zein NN","year":"1996","journal-title":"Current trends and future implications"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-78-1-45"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.34.2.417-423.1996"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.223-235.2000"},{"key":"e_1_2_7_15_2","first-page":"1","article-title":"Methods for determining the hepatitis C genotype","volume":"4","author":"Xavier F","year":"1998","journal-title":"Viral Hepatitis Rev"},{"key":"e_1_2_7_16_2","first-page":"634","article-title":"Hepatitis C virus genotypes in the United States","volume":"125","author":"Zein NN","year":"1996","journal-title":"Epidemiology, pathogenicity, and response to interferon therapy"},{"key":"e_1_2_7_17_2","first-page":"13","article-title":"Hepatitis C virus genotypes","volume":"19","author":"Dusheiko G","year":"1994","journal-title":"An investigation of type-specific differences in geographic origin and disease"},{"key":"e_1_2_7_18_2","first-page":"884","article-title":"Geographical distribution of hepatitis C virus genotypes in blood donors","volume":"32","author":"McOmish F","year":"1994","journal-title":"An international collaborative survey"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-3-199502010-00001"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80205-3"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1607"},{"key":"e_1_2_7_22_2","first-page":"571","article-title":"Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria","volume":"59","author":"Abdulkarim AS","year":"1998","journal-title":"Identification of two novel hepatitis C virus subtypes"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-78-6-1341"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80154-8"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.3.546-568.2003"},{"key":"e_1_2_7_26_2","first-page":"631","article-title":"Hepatitis C and renal disease","volume":"42","author":"Meyers CM","year":"2003","journal-title":"An update"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1654(199904\/06)9:2<101::AID-RMV234>3.0.CO;2-U"},{"key":"e_1_2_7_28_2","first-page":"129","article-title":"Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain","volume":"60","author":"Baril G","year":"2003","journal-title":"Effect of time, initiating HCV prevalence studies and adoption of isolation measures"},{"key":"e_1_2_7_29_2","first-page":"780","article-title":"Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy","volume":"9","author":"Fabrizi F","year":"1994","journal-title":"Prevalence, risk factors and relationship to liver disease"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp6.81"},{"key":"e_1_2_7_31_2","first-page":"477","article-title":"Patient to patient transmission of hepatitis C virus in hemodialysis units","volume":"55","author":"Taskapan H","year":"2001","journal-title":"Clin Nephrol"},{"key":"e_1_2_7_32_2","first-page":"133","article-title":"Hepatitis C infection among patients receiving hemodialysis","volume":"24","author":"Kamar N","year":"2003","journal-title":"Nephrologie"},{"key":"e_1_2_7_33_2","first-page":"263","article-title":"Transmission of the hepatitis C virus in an hemodialysis unit","volume":"47","author":"Olmer M","year":"1997","journal-title":"Evidence for nosocomial infection"},{"key":"e_1_2_7_34_2","first-page":"51","article-title":"Hepatitis C virus infection in dialysis","volume":"23","author":"Pereira BJ.","year":"1999","journal-title":"A continuing problem"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.123"},{"key":"e_1_2_7_36_2","first-page":"2335","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents","volume":"65","author":"Fissell RB","year":"2004","journal-title":"The DOPPS"},{"issue":"10","key":"e_1_2_7_37_2","first-page":"159","article-title":"Development of renal replacement therapy in Poland","volume":"19","author":"Rutkowski B","year":"2006","journal-title":"J Nephrol"},{"key":"e_1_2_7_38_2","first-page":"183","article-title":"Prevention of viral transmission in HD units","volume":"17","author":"Karkar A","year":"2006","journal-title":"The value of isolation"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00787-X"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050456"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00314-2"},{"key":"e_1_2_7_42_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/jcm.35.1.187-192.1997","article-title":"Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2 and 3 by quantiplex HCV RNA assay, and an in\u2010house limiting dilution method","volume":"35","author":"Havkins A","year":"1997","journal-title":"J Clin Microbiol"},{"key":"e_1_2_7_43_2","first-page":"121","article-title":"Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C","volume":"12","author":"Lu RH","year":"1998","journal-title":"Comparison between Amplicor HCV monitor system and branched DNA signal amplification assay"},{"key":"e_1_2_7_44_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/jcm.33.1.209-211.1995","article-title":"Serological reactivity and viral genotypes in hepatitis C virus infection","volume":"33","author":"Maggi F","year":"1995","journal-title":"J Clin Microbiol"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp4.9"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.15"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1159\/000189318"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.19897"},{"key":"e_1_2_7_49_2","first-page":"141","article-title":"Known and probable risk factors for hepatitis C infection","volume":"12","author":"Chlabicz S","year":"2006","journal-title":"A case series in north-eastern Poland"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70310-6"},{"key":"e_1_2_7_51_2","first-page":"639","article-title":"Low prevalence of hepatitis C virus infection in hemodialysis units","volume":"24","author":"Harmonkaya O","year":"2002","journal-title":"Effect of isolation"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp1.2"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.21294"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1159\/000190287"},{"key":"e_1_2_7_55_2","first-page":"59","article-title":"Hand\u2010borne mechanisms of dissemination of hepatitis C virus in dialysis units","volume":"51","author":"Caramelo C","year":"1999","journal-title":"Basis for new addenda to the present preventive strategies"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000093252"},{"key":"e_1_2_7_57_2","first-page":"372","article-title":"Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran","volume":"11","author":"Amiri ZM","year":"2005","journal-title":"East Mediterr Health J"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.39"},{"key":"e_1_2_7_59_2","first-page":"42","article-title":"European study on epidemiology and management of hepatitis C virus (HCV) infection in the haemodialysis population. Part 3","volume":"32","author":"Zampieron A","year":"2006","journal-title":"Prevalence and incidence"},{"key":"e_1_2_7_60_2","first-page":"13","article-title":"The role of hemodialysis machines dedication in reducing hepatitis C transmission in the dialysis setting in Iran","volume":"5","author":"Shamshirsaz AA","year":"2004","journal-title":"A multicenter prospective international study"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-6-237"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.19"},{"key":"e_1_2_7_63_2","first-page":"367","article-title":"Hepatitis C virus genotypes in hemodialyzed patients","volume":"47","author":"Goessens C","year":"1997","journal-title":"A multicentric study"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118842"},{"key":"e_1_2_7_65_2","first-page":"354","article-title":"Hepatitis C genotypes in liver transplant recipients","volume":"1","author":"Zein NN","year":"1995","journal-title":"Distribution and 1-year follow-up"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.1.232-234.1994"},{"key":"e_1_2_7_67_2","first-page":"445","article-title":"Interferon therapy in chronic hepatitis C virus","volume":"45","author":"Pozzato G","year":"1995","journal-title":"Evidence of different outcome with respect to different viral strains"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210204"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.2"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.8.1669"},{"key":"e_1_2_7_71_2","first-page":"S105","article-title":"Hepatitis C 2002 guidelines","volume":"239","author":"Orlent H","year":"2003","journal-title":"Summary and annotations"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp4.16"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp4.25"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp4.31"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/11.supp4.22"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.42"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.49"},{"key":"e_1_2_7_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00423-2"},{"key":"e_1_2_7_79_2","first-page":"886","article-title":"Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection","volume":"46","author":"Pereira BJ","year":"1994","journal-title":"A U.S. National collaborative study"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.52"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655902762467657"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188715"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2001.10212.x"},{"issue":"8","key":"e_1_2_7_84_2","first-page":"55","article-title":"Systematic evaluation of liver disease in hepatitis C virus\u2010infected renal transplant recipients","volume":"15","author":"Berthoux F","year":"2000","journal-title":"Clinical and pathological study"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.suppl_8.60"},{"key":"e_1_2_7_86_2","first-page":"1890","article-title":"Impact of hepatitis C virus on renal transplantation","volume":"38","author":"Pedroso S","year":"2006","journal-title":"Association with poor survival"},{"issue":"4","key":"e_1_2_7_87_2","first-page":"48","article-title":"HCV liver disease in renal transplantation","volume":"11","author":"Haem J","year":"1996","journal-title":"A clinical and histological study"},{"key":"e_1_2_7_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.403"},{"key":"e_1_2_7_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000090743.43034.72"},{"key":"e_1_2_7_90_2","first-page":"617","article-title":"Transplantation of kidneys from HCV\u2010positive donors","volume":"16","author":"Fabrizzi F","year":"2003","journal-title":"A safe strategy?"},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi231"},{"issue":"1","key":"e_1_2_7_92_2","first-page":"207","article-title":"Therapy of hepatitis C","volume":"43","author":"Pawlotsky JM.","year":"2006","journal-title":"From empiricism to eradication"},{"key":"e_1_2_7_93_2","first-page":"51","article-title":"Interferon therapy for chronic hepatitis C in hemodialysis patients","volume":"80","author":"Uchihara M","year":"1998","journal-title":"Increased serum levels of interferon"},{"key":"e_1_2_7_94_2","first-page":"1610","article-title":"Interferon monotherapy for dialysis patients with chronic hepatitis C","volume":"98","author":"Russo MW","year":"2003","journal-title":"An analysis of the literature on efficacy and safety"},{"key":"e_1_2_7_95_2","first-page":"353","article-title":"Peginterferon alfa\u20102b in patients with chronic hepatitis C","volume":"16","author":"Juszczyk J","year":"2004","journal-title":"Pol Merk Lek"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.1159\/000045971"},{"key":"e_1_2_7_97_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.6.651"},{"key":"e_1_2_7_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01225.x"},{"key":"e_1_2_7_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"key":"e_1_2_7_100_2","first-page":"958","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns MP","year":"2001","journal-title":"A randomised trial"},{"key":"e_1_2_7_101_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_7_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00680.x"},{"key":"e_1_2_7_103_2","first-page":"287","article-title":"Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection","volume":"8","author":"Bruchfeld A","year":"2001","journal-title":"A pilot study"},{"key":"e_1_2_7_104_2","first-page":"1573","article-title":"Interferon and ribavirin treatment in patients with hepatitis C","volume":"18","author":"Bruchfeld A","year":"2003","journal-title":"Associated renal disease and renal insufficiency"},{"key":"e_1_2_7_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.07.025"},{"key":"e_1_2_7_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00710-X"},{"key":"e_1_2_7_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260721"},{"key":"e_1_2_7_108_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_7_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392102"},{"key":"e_1_2_7_110_2","first-page":"1745","article-title":"Outcome of kidney transplant in chronic hepatitis C virus patients","volume":"35","author":"Gonzales\u2010Roncero F","year":"2003","journal-title":"Effect of pretransplantation interferon-alpha2b monotherapy"},{"key":"e_1_2_7_111_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000079613.81511.3C"},{"issue":"8","key":"e_1_2_7_112_2","first-page":"74","article-title":"Treatment of hepatitis C virus infection after renal transplantation","volume":"15","author":"Rostaing L.","year":"2000","journal-title":"New insights"},{"issue":"1","key":"e_1_2_7_113_2","first-page":"135","article-title":"Long\u2010term results of treatment of chronic hepatitis B, C and D with interferon\u2010alpha in renal allograft recipients","volume":"11","author":"Durlik M","year":"1998","journal-title":"Transplant Int"},{"issue":"1","key":"e_1_2_7_114_2","first-page":"343","article-title":"Treatment of chronic hepatitis B and C with interferon\u2010alpha in renal allograft recipients","volume":"7","author":"Durlik M","year":"1994","journal-title":"Preliminary results"},{"key":"e_1_2_7_115_2","first-page":"677","article-title":"Chronic hepatitis C virus infection in renal transplant","volume":"20","author":"Sharma RK","year":"2006","journal-title":"Treatment and outcome"},{"key":"e_1_2_7_116_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225569.04773.8b"}],"container-title":["Hemodialysis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1542-4758.2007.00181.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1542-4758.2007.00181.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:55:35Z","timestamp":1697352935000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1542-4758.2007.00181.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,15]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1542-4758.2007.00181.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1542-4758.2007.00181.x","archive":["Portico"],"relation":{},"ISSN":["1492-7535","1542-4758"],"issn-type":[{"value":"1492-7535","type":"print"},{"value":"1542-4758","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,15]]}}}